Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
ARE Transcript
Alexandria Real Estate Equities, Inc. (ARE) Q4 2025 Earnings Call Transcript
Unknown1-27
The earnings call reveals several concerns: declining occupancy, reduced FFO guidance, and challenges in leasing due to oversupply. The Q&A highlights uncertainties in the biotech sector and cautious funding, which could affect future leasing. Additionally, the company plans significant asset dispositions, indicating potential financial strain. Despite some positive leasing activity, the overall sentiment is negative, reflecting a challenging environment. The lack of guidance for 2027 and increased free rent further contribute to the negative outlook. Given these factors, the stock price is likely to experience a negative movement in the short term.
Alexandria Real Estate Equities, Inc. (ARE) Q3 2025 Earnings Call Transcript
Unknown10-28
The earnings call presents a mixed picture: while there are positive elements like strong asset demand and a strategic focus on Megacampuses, concerns remain about regulatory impacts, market uncertainty, and unresolved asset impairments. The lack of immediate guidance for 2026 and the cautious approach towards dividends and buybacks indicate a conservative stance. These factors balance each other out, leading to a neutral sentiment.
Alexandria Real Estate Equities, Inc. (ARE) Q2 2025 Earnings Call Transcript
Unknown7-22
The earnings call highlighted strong leasing activity and a healthy dividend payout, but reduced FFO guidance and same property NOI growth. Concerns in the Q&A about free rent trends, occupancy trajectory, and NIH funding issues add uncertainty. Despite optimistic long-term growth, the lack of clear guidance and specifics on key issues tempers positive sentiment, leading to a neutral rating.
Earnings call transcript: Alexandria RE Q1 2025 misses EPS forecast
Unknown4-29
The earnings call presents a mixed picture: solid financial performance with a 4% revenue increase and strong dividend yield, but concerns in the biotech sector and a slight occupancy decline. The Q&A reveals uncertainties, particularly in the biotech market and capital raising, with management's cautious tone. The company's strategic focus on innovation and solid liquidity position are positives, but the guidance reflects potential challenges. Given these factors, the stock price is likely to remain stable, with a neutral sentiment over the next two weeks.
ARE Slides
ARE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
